Role of somatostatin analogue-based therapy in unresponsive malignant thymomas

Giovannella Palmieri, Secondo Lastoria, Liliana Montella, Angelo Martignetti, Gaetano Lombardi, Marco Salvatore, Angelo Raffaele Bianco

Research output: Contribution to journalArticlepeer-review


Thymomas are rare neoplasms that are usually associated with parathymic syndromes, pure red cell aplasia, myasthenia gravis, hypogammaglobulinaemia and other mainly immunological disorders. Therefore, the management of thymoma patients is often complex and presents many diagnostic and therapeutic issues. Controversies concerning the definition of the histological subtypes and the role played by thymoma-associated syndromes are of primary importance in determining the oncological approach. Although low-stage thymomas have a high percentage of recovery, thymomas which are locally advanced, metastatic or previously treated with standard therapeutic options have no well-defined and effective treatment approaches. The data previously described by us on somatostatin receptor scintigraphy showing high uptake of indium-labelled octreotide by thymic masses and the successful treatment of a patient with thymoma and pure red cell aplasia with octreotide and prednisone has provided us the rationale for using such treatment in patients with advanced thymoma.

Original languageEnglish
Pages (from-to)80-85
Number of pages6
JournalAnnals of Medicine
Issue numberSUPPL. 2
Publication statusPublished - Oct 1999


  • Lanreotide
  • Octreotide
  • Scintigrapfhy
  • Somatostatin
  • Thymoma

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Role of somatostatin analogue-based therapy in unresponsive malignant thymomas'. Together they form a unique fingerprint.

Cite this